The potential oral toxicity of 1,3-dichloropropene (1,3-D) has been evaluated in a number of dietary toxicity studies. The relatively high vapor pressure of 1,3-D, its short half-life in drinking water, and its reactivity with constituents of feed necessitated the use of a microencapsulated formulation (starch-sucrose shell) of 1,3-D in these studies. The bioavailability of ingested microencapsulated 1,3-D was determined by characterizing and comparing the kinetics of 1,3-D in the blood of female F344 rats coadministered microencapsulated 1,3-D and neat 13 C-1,3-D (25 mg/kg each) via gavage. Blood concentrations of total or cis-and rnans-isomers of 1,3-D in treated rats were determined using gas chromatography-mass spectroscopy (GC-MS) or in situ membrane extraction MS. Urine was also collected and analyzed by GC-MS for the presence of the mercapturate excretion product of 1,3-D [N-acetyl-S-(3-chloropropenyl-2>L-cysteine; 1,3-DMA]. Blood levels of 1,3-D and U C-1,3-D displayed similar kinetics, peaking within 10 min of dosing followed by a rapid biphasic elimination. Higher peak blood levels and greater blood curve areas (AUC) were attained for trans-than os-l,3-D and 13 C-1,3-D and greater amounts of cis-than tarns-1,3-DMA and 13 C-1,3-DMA were excreted in the urine consistent with the known rapid and disproportionate glutathione conjugation of the cis-isomer in the gastric mucosa. Slightly higher cis-l^-D than cis-13 C-l,3-D blood levels and AUCs were also consistently noted while the reverse was true for urinary excretion of cis-I3 C-13-DMA and c£s-l,3-DMA suggesting that 1,3-D derived from microencapsulated test material may be absorbed and/or metabolized in the stomach mucosa at a slightly slower rate than that from neat material. The latter, however, would be of no consequence during the administration of 1,3-D to animals via their diets as competing test materials would not be present and 1,3-D blood kinetics were unaffected. Overall, the results of this study demonstrate the ready bioavailability of microencapsulated 1,3-D and rapid elimination of 1,3-D from the blood of rats.
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' To whom correspondence should be addressed. Microencapsulation is a process in which compounds are surrounded by a continuous, uniform coating for the purpose of separating them from their environment (Sparks, 1981) . This technique has been used for a number of years in the pharmaceutical industry to improve drug stability, mask tastes, and provide controlled release of drugs (Luzzi and Palmieri, 1984; Sparks, 1981) , but has only recently begun to be applied in the toxicity testing of volatile and/or potentially reactive chemicals. In particular, microencapsulation in food-grade materials has provided an economical means of administering these compounds to test animals via their diet (Jameson et al, 1988; Kuhn et al, 1988; Melnick et al., 1987a) . If stored appropriately, even relatively reactive chemicals may remain stable within a compatible microencapsulation matrix or "shell" for extended periods of time. When mixed with an animal's diet, the chemical may be ingested and released as the shell dissolves in the aqueous environment of the enteric tract. In this way, the bolus administration of chemicals with the resultant artificially high or "spike" blood and tissue concentrations may be avoided. In addition, the microencapsulation of chemicals also avoids the use of vehicle compounds which may artificially alter the absorption of test materials from the enteric tract and cause treatment-related effects of their own (Eustis and Boorman, 1985; Haseman et al, 1985; Shinkuma et al, 1981; Scheuplein et al, 1990) .
The ready and complete disolution of microcapsules and release of encased chemical once ingested by test animals is critical to the use of this technology in toxicity testing. Dosing and absorption of a test material should reflect as closely as possible the ingestion of test diets rather than the dissolution of encapsulation matrices. Indeed, the immediate release of microencapsulated compounds within the enteric tract resulting in comparable pharmacokinetics and biological activities of microencapsulated chemicals with that of neat chemicals has been demonstrated for several com--pounds. Jameson et al. (1988) reported similar peak blood concentrations, time to peak blood levels and total area under blood concentration curve measurements (AUC) for 1,1,1-trichloroethane or 2-ethylhexanol when administered either encapsulated in a starch-sucrose shell or neat chemical in a corn oil vehicle via bolus oral gavage. The toxicity of several chemicals administered to rats via their diets as microencapsulated products or as oil vehicle solutions also have been compared and found to be similar when adjusted for the bolus versus nonbolus nature of the dosing (Aida et al., 1989; Melnick et ai, 1987b) . In this way the biological availability of microencapsulated chemicals and neat chemical-vehicle mixtures has been determined to be equivalent or "bioequivalent," the latter having a regulatory interpretation as different methods resulting in the same rate and extent of systemic availability of a chemical (Cabana, 1977; US-FDA, 1977) . The mixed isomers of 1,3-dichloropropene (1,3-D) are the active ingredients of a number of agricultural nematocides. 1,3-D has a vapor pressure of approximately 26-28 mm Hg at 25°C, has a relatively short half-life in drinking water, and reacts with proteins and nonprotein sulfhydryls (Climie et ai, 1979; Creedy et ai, 1984; Dietz et ai, 1984a; W. Stott, unpublished data) . These properties have made it impossible to effectively administer a specific dosage of the neat chemical to test animals via their diet or drinking water. Thus, previous oral toxicity studies of 1,3-D have utilized the bolus dosing of a neat 1,3-D-corn oil solution as a means of delivery to rats and mice (NTP, 1985; Yang et ai, 1986) . Subsequently, it was found that 1,3-D could be encapsulated in a starch-sucrose matrix, mixed in powdered rodent feed, and administered to test animals via their diets thus avoiding the use of bolus oral dosing (Haut et al., 1996; Stott et al., 1996) . The present study was undertaken to evaluate the bioequivalence of ingested microencapsulated 1,3-D by comparing the kinetics of 1,3-D in the blood of rats coadministered microencapsulated and neat 1,3-D.
MATERIALS AND METHODS
Study design. The bioavailability of microencapsulated and neat 1,3-D administered via oral gavage in corn oil was determined by quantitating the concentration of individual isomers of 1,3-D and/or total 1,3-D in the blood and calculating maximum concentration attained, time to peak blood concentration, and AUCs for each delivery method. The urinary excretion of a mercapturate metabolite of 1,3-D following dosing also was measured in some animals. The blood concentration of a chemical over time provides a measure of the dynamics of systemic exposure, and similar total blood AUCs of a compound administered via two methods indicates similar systemic bioavailability. Likewise, the excretion of similar levels of a major metabolite of a chemical from the treated animals provides further evidence they had received a similar dosage of the compound via the two methods of administration.
The study consisted of two phases. In Phase I, six fasted female Fischer 344 rats fitted with indwelling jugular cannulas were coadministered 25 mg/ kg dosages each of neat I3 C-1,3-D and microencapsulated (starch-sucrose matrix) 1,3-D (normal isotopic, I2 C-1,3-D) in a single com oil solution/ suspension via oral gavage. Dosed rats were placed in all-glass metabolism cages, blood samples were collected over the first hour, and urine samples were collected over the first 48 hr postdosing. Blood concentrations of cis-and trans-I3 C-1,3-D and 1,3-D and urinary concentrations of the Nacetylcysteine conjugates of cis-and transn C-1,3-D and 1,3-D (A'-acetyl-S-(3-chloropropenyl-2)-L-cysteine; I3 C-I,3-DMA and 1,3-DMA, respectively), the primary urinary excretion products of 1,3-D in rats (Climie et al., 1979; Dietz et al., 1984b; Fisher and Kilgore, 1988a; Onkenhout et ai, 1986; Waechter and Kastl, 1988) , were quantitated by GC-MS. Values were averaged and plotted and uptake and elimination rate constants in blood and areas under the blood curves were subsequently calculated.
In Phase II of the study, six fasted female Fischer 344 rats fitted with indwelling hollow fiber membrane probes (see below) in their right jugular veins were coadministered neat "C-1,3-D and microencapsulated 1,3-D in a single com oil solution/suspension via oral gavage. Two of the treated rats were subsequently allowed free access to feed and were used again to generate blood kinetic data on consecutive days resulting in a total of 10 trials in which data were generated. Animals were dosed with 25 or 50 mg/ kg of neat "C-1,3-D. The first three rats, involving a total of seven trials, were also administered like dosages of microencapsulated 1,3-D. However, due to the poor loading efficiency of a second batch of microencapsulated 1,3-D utilized, three of the naive animals used, involving a single trial each, were dosed with only 30% of the targeted dosage of microencapsulated 1,3-D. Blood levels of appropriate ions generated from each compound were then monitored in real time over an approximately 1-hr period. Blood AUCs for total I3 C-1,3-D and 12 C-1,3-D were calculated, normalized for dosage if necessary, and compared as a percentage of the total for each animal.
The total dosages of 50 mg/kg (Phase I and II) or 100 mg/kg (Phase II) 1,3-D employed in the study have been shown to cause a depression in stomach glutathione levels in rats (Dietz et al., 1984a, Fisher and Kilgore, 1988b) and are associated with treatment-related toxicity in this organ (Haut et ai, 1996; NTP, 1985; Stott et ai, 1986) . However, administration of up to 100 mg/kg 1,3-D does not appear to significantly saturate the overall metabolism and excretion of this compound in rats (Dietz et ai, 1984b; Waechter and Kastl, 1988) . It was assumed, therefore, mat blood, 1,3-D AUCs and kinetics were linearly related to administered dosage in the present study. Kaye et ai (1972) .
Hollow fiber membrane probes were prepared as follows: Silastic Rx65 medical grade tubing (0.015 X 0.023 in.), a poly(dimethylsiloxane) elastomer, was used as the sensing membrane. This was supported internally with 3 X 2 lb Dupont Stren monofilaments epoxied to the free end of the membrane, creating a vacuum-tight seal. The other end of the membrane was stretched over one end of a 1-cra length of thin-wall 25-gauge stainlesssteel tubing and anchored in place with Dow Corning RTV 732 multipurpose sealant. The open end of the tubing was inserted 5 mm into a 48-cm piece of 22-gauge thin-walled Teflon tubing and epoxied in place, leaving an open channel from the membrane surface through the Teflon tubing to the mass spectrometer. The Teflon tubing was etched with Polyetch, a sodium tetraethylene glycol dimethyl ether etching solution, and flushed with water, medianol, and acetone. This etching ensured good adhesion between the epoxy and die Teflon surface. The outer surface of the Teflon line was also etched and two polyethylene collars were epoxied at diese Animals and animal husbandry. Female Fischer 344 rats were obtained from Charles River Breeding Laboratories (Kingston, NY) for use in all phases of the study. Animals used in Phase 1 of the study were 11 -12 weeks of age while those used in Phase II of the study were 2-6 months of age when used. Animals were provided Purina Certified Rodent Chow No. 5002 (Purina Mills Inc., St. Louis, MO) (except during fasting periods) and tap water ad libitum. In Phase I, rats were uniquely identified by tail marks and surgically fitted with an indwelling jugular vein cannula (Silastic; 0.020 inch ID X 0.037 in. OD). In Phase II, rats were surgically fitted with hollow fiber membrane probes (see above) while under methoxyflurane anesthesia using the method outlined by Harms and Ojeda (1974) , with minor modifications regarding attachment sites. In the latter case, rats were fitted with a rodent jacket equipped with a protective spring cannula holder. Animals were provided a 24-to 48-hr recovery period prior to use.
Dosing. Dosing solutions were prepared immediately prior to dosing by mixing together a measured volume of neat I3 C-1,3-D and a weighed amount of microencapsulated 1,3-D to a preweighed volume of com oil (USP grade) in a capped glass vial with limited headspace. Analysis of freshly prepared microencapsulated 1,3-D suspensions in corn oil revealed no leakage of encapsulated 1,3-D into the com oil. Dosing solutions were administered to rats via oral gavage using a I -cc tuberculin syringe equipped with a 16-gauge feeding needle. A roughly even suspension of microcapsules in the dosing suspension was maintained by repetitive inversion of vials and syringes prior to injection. Animals were administered a dosing volume of 2 ml/kg with an additional 0.2 ml "chaser" volume of com oil to ensure complete delivery of the test matenal(s). Thus, volume delivered, not syringe weights, were used to determine the exact dosage delivered.
Blood concentrations of cis-and trans-1,3-dichloropropene.
In Phase I of the study, up to 10 blood samples of approximately 0.2 ml each were collected from the jugular cannula of dosed rats over the first hour postdosing. The cannula was first cleared of the hepann lock, the blood sample was collected, and approximately 0.3 ml of heparinized saline was injected into the cannula providing a fresh heparin lock. Upon collection, blood samples were immediately injected into weighed septum-sealed vials and the concentrations of cis-and trans-' y C-1,3-D and 1,3-D were then quantitated using GC-MS. Briefly, blood samples were fortified with D t -1,3-D (1:1; as:trans) and extracted into approximately 0.1 ml hexane. Separation was achieved using a 30-m DB-624 capillary column (0.32 mm i.d., 1.8 /im film thickness) with a temperature programming (2 min hold at 50°C initial temperature, ramp to 120°C at IO°C/min, followed by a second ramp to 250°C at 307min). The mass spectrometer (Finnigan TSQ 70) was operated in the electron impact mode, monitoring ions mlz 75 ( I2 C-I,3-D), and mlz 76 ( I3 C-I,3-D), and mlz 79 (D 4 -l,3-D) at 100 msec/ion/scan. Following normalization of the I3 C data for dosage of individual isomers, absorption and excretion constants, half-lives, and blood AUCs were calculated as described by Gibaldi and Perrier (1975) with the aid of the commercial WinNonlin program (Scientific Consulting, Inc., Apex, NC). Absorption kinetics in Phase I were calculated based upon the composite blood curves due to the limited number of data points available.
In Phase II of the study, blood levek of I2 C-13-D and I3 C-1,3-D were monitored in situ by using implanted hollow fiber membrane probes coupled directly to a mass spectrometer. Just prior to dosing, the probes were connected to the mass spectrometer, evacuated, and used to directly monitor the two forms of 1,3-D ( 12 C-I,3-D and "C-1,3-D) at mlz = 75 and mlz = 76, respectively. The selective permeation of 13-D through the Silastic membrane material afforded rapid and sensitive real-time detection on the mass spectrometer. The relative levels of 1,3-D were monitored continuously from 5 min predosing to approximately 30 min postdosing at a rate of approximately 60 measurements/min. These data were plotted, and the relative percentage of total AUC represented by each form of 13-D was subsequently calculated for each animal. Kinetic constants were also calculated for a representative animal by plotting 50 point averages of the response intensity versus time post-dosing as referenced above. Kinetic constants shown in Table 1 for the absorption and excretion of 1,3-D in these animals were calculated by averaging the values from six separate experiments.
Potential ' 'crossover'' of 12 C from D 4 and I3 C isotopes used was corrected for as appropriate. As noted, blood AUC data for microencapsulated 1,3-D obtained in three of six rats in Phase n of the study also had to be normalized for total 1,3-D dose received due to the unusually low loading of the particular lot of microencapsulated 1,3-D used (12 versus 38% in the remainder of the study).
Urinary mercapturic acid conjugate of 1,3-dichloropropene.
Rats in Phase I of the study were housed in all glass metabolism cages following dosing. Urine was collected from dosed rats for 48 hr postdosing. Samples were collected on dry ice and stored at -80°C until analysis. Urinary concentrations of cis-and fnanj-l,3-DMA and I3 C-1,3-DMA were quantitated by GC-MS Briefly, this method is involved the fortification of urine samples (1 ml) with D 4 -1,3-DMA (1:1; cis.trans) followed by acidification and extraction with ethyl acetate. Following methylation with ethereal diazomethane, the samples were evaporated to dryness under a gentle stream of nitrogen, reconstituted in 1 ml ethyl acetate, and analyzed by GC/MS. Separations were achieved on a 15-m DB-1701 capillary column (0.32 mm i.d., 1.0 |xm film thickness) using a temperature program (1 min hold at 160°C initial temperature, ramp to 195°C at 5°C/min, followed by a second ramp to 275°C at 257min). The mass spectrometer (Finnigan TSQ 70) was operated in the electron impact mode, monitoring ions mlz 251 (1,3-DMAMe), mlz 252 ("C-1,3-DMA-Me), and mlz 255 (D 4 -1,3-DMA-Me) at 50 msec/ion/scan.
Statistics. Blood 1,3-D AUC and urinary 1,3-DMA excretion data were analyzed using a paired t test (Steel and Torrie, 1960) .
RESULTS

Stability.
The starch-sucrose microcapsules containing 1,3-D used in the study were quite stable in corn oil. Analysis of freshly prepared suspensions of microencapsulated 1,3-D in food grade corn oil (USP grade) which had been centrifuged at relatively low speed and/or filtered through several layers of cheese cloth to remove particulates, revealed no leakage of 1,3-D into the vehicle. Even upon prolonged refrigerated storage of a suspension of microencapsulated 1,3-D for 3.5 months, less than 1% of the added 1,3-D was detected in the corn oil vehicle.
Blood concentrations of 1,3-D.
Blood concentration data for cis-and trans-1,3-D in rats coadministered 25 mg/kg of both neat 13 C-1,3-D and microencapsulated 1,3-D Phase I of the study are displayed in Fig. 1 and 2 . A representative blood concentration curve based upon ion intensity data generated in Phase II of the study is shown in Fig. 3 . Pharmacokinetic and AUC data from both phases of the study are summarized in Table 1 . Blood concentration curves from 6 of the 10 total trials in Phase II provided data suitable for calculating pharmacokinetic constants. In some instances blockage of the probe occurred due to crimping or clot formation resulting in irregular shaped curves in some cases.
In general, oral administration of microencapsulated 1,3-D resulted in higher blood concentrations of 1,3-D in the blood of rats than oral administration of equal dosages of neat I3 C-1,3-D (Fig. 1-3) . The only exceptions noted were in Phase I of the study in which mean peak blood levels of trans-]3 C-1,3-D originating from neat test material approxi- mated those originating from microencapsulated material (Fig. 2) and in 1/10 trials in Phase II of the study in which the blood levels of I3 C-1,3-D were higher than 1,3-D. The use of fed as opposed to fasted rats in Phase II of the study did not have any noticeable impact upon the relative blood concentrations of the two isotopes obtained (data not presented separately).
Blood AUC values calculated from blood curves are shown in Table 1 . Roughly equivalent blood AUC values were calculated for 1,3-D derived from microencapsulated 1,3-D and neat 13 C-1,3-D in Phase I of the study, 54 and 46% of the total AUCs, respectively. In Phase II of the study, however, the proportion of the total AUC attributed to microencapsulated and neat test materials in normalized data was calculated to be 66 and 34%, respectively.
In both phases of the study, peak blood concentrations were reached within 10 min of dosing followed by an over 10-fold decrease in concentration within 30-60 min postdosing ( Fig. 1 -3 ). Blood AUCs and peak blood levels of trans-1,3-D were consistently higher than those of cis-1,3-D, regardless of whether microencapsulated or neat 1,3-D was administered (Fig. 1-3 and Table 1) . trans-l,3-D derived from microencapsulated and neat 1,3-D accounted for 78% of the total blood AUCs (i.e., cis-plus trans-\,3-D) in Phase I of the study.
Despite a relatively large degree of interanimal variability in the blood concentrations of 1,3-D, blood data provided enough resolution to define the uptake and elimination kinetics of orally administered 1,3-D in rats. Absorption half-lives of roughly 1.3-5.5 min were calculated for both isomers of 1,3-D (Table 1 ). Once absorbed, 1,3-D was eliminated from the blood of rats in a biphasic manner consisting of a relatively rapid alpha-phase with a half-life of approximately 5-7 min and a slower beta-phase with a half-life of approximately 20-43 min.
Urinary excretion of 1,3-DMA. The relative amounts of cis-and trans-1,3-DMA and 13 C-1,3-DMA in the urine of rats coadministered neat and microencapsulated 1,3-D in Phase I of the study are presented in Table 2 . Slightly less (approximately 16%) cis-1,3-DMA derived from microencapsulated 1,3-D relative to cwl3 C-l,3-DMA derived from neat I3 C-1,3-D was excreted in the urine of treated rats. In contrast, nearly equivalent amounts of trans isomers of 1,3-DMA and I3 C-1,3-DMA were excreted. The net effect upon total 1,3-D excretion was that slightly less 1,3-DMA (microencapsulated) (44%) was excreted than I3 C-1,3-DMA (neat) (56%). 
DISCUSSION
The potential of 1,3-D encapsulated in a starch-sucrose matrix to be absorbed upon ingestion by rats relative to the absorption of neat 1,3-D was determined primarily by the comparison of blood kinetic data obtained in rats. Dosing of individual rats with a single form of the test materials, neat 1,3-D or microencapsulated 1,3-D, had resulted in a relatively large degree of interanimal variability in 1,3-D blood levels (data not shown). It also appeared that 1,3-D was rapidly absorbed upon ingestion requiring that a relative large number of blood samples be obtained within a short time of dosing. Thus, several relatively novel experimental methods were employed in the study. The coadministration of two isotopic forms of the test material, I2 C-1,3-D and 13 C-1,3-D, to the same animals in Phase I of the study lessened the potential impact of interanimal physiological differences and decreased potential experimental and analytical error. Variability observed in the study data thus more truly reflected interanimal differences in the pharmacokinetics of 1,3-D.
The use of an implanted, selectively permeable, hollowfiber probe to generate continuous, near real-time, blood concentration data in Phase II of the study eliminated the need for wet chemistry methods in the analysis of blood 1,3-D levels. The latter procedure also ensured that a complete concentration time curve could be examined postdosing, no matter how rapidly absorption occurred. Unfortunately, the application of hollow-fiber technology in this particular instance did not allow the generation of data for individual isomers; ions corresponding to different isotopes of carbon and not different isomers of 1,3-D were continuously monitored by mass spectrometry. Neither was the calculation of absolute concentration data possible since performance of a given probe may vary among animals and with time as positional changes within the vein and clotting may alter the effective sampling surface areas. The slight differences in the isomeric ratios of the microencapsulated 1,3-D and neat of the study. These findings are consistent with a slightly higher rate of absorption and glutathione conjugation of neat cis-{1 C-1,3-D in the stomach mucosa than of microencapsulated 1,3-D. The c/'s-isomer of 1,3-D in particular readily undergoes nonenzymatic and enzymatic conjugation with glutathione (Climie et al., 1979; Creedy et al., 1984) of which relatively high concentrations have been reported in the gastric mucosa of rats (Boyd et al., 1979) . The newly formed conjugate would still be available for further metabolism and excretion as I3 C-1,3-DMA in the urine thus also explaining the apparently paradoxical observation of slightly higher levels of dsl3 C-l,3-DMA than c«-l,3-DMA in the urine of treated rats, 58 and 42% of the total, respectively. The lack of significant differences in the blood curves of fed versus fasted rats in Phase II of the study (data not given separately) indicates that extensive conjugation with glutathione in the stomach lumen and subsequent absorption was likely not a major factor in lowering blood levels of cisn C-1,3-D. It is important to recognize, however, that whatever slight differences may exist in the absorption and/ or localized gastric metabolism of the two formulations of 1,3-D, they would appear to be of little consequence to the ultimate 1,3-D body burden achieved in an animal ingesting 1,3-D as part of its diet. Not only would potentially competing neat 1,3-D not be present, but the normal variability in rodent feed intake patterns would override any minimal differences in uptake kinetics.
The results of the study also provided the first comprehensive information on the blood kinetics of 1,3-D following oral administration to rats. Half-lives of absorption of 1,3-D from the stomachs of treated rats, regardless of the form administered, ranged from roughly 1.3 to 5.5 min, indicating a relatively rapid uptake of 1,3-D once ingested. Peak blood concentrations of 1,3-D were typically achieved within 10 min of dosing with that of trans-1,3-D exceeding cis-\,3-D by 3-to 6-fold, reflecting the preferential metabolism of the latter isomer by conjugation with glutathione (Climie et al., 1979 , Dietz et al., 1984b Onkenhout et al., 1986 ; Waechter mately a 4% difference in isomer dosages to experimental animals, an insignificant factor when the average coefficient of variability in animal data was 34%.
The results of the study demonstrated the equivalent, if not greater, systemic bioavailability of 1,3-D encapsulated in a starch-sucrose matrix relative to neat 1,3-D. Similar kinetic parameters were observed for 1,3-D originating from either form of test materials; however, in most instances, higher peak blood levels of cis-1,3-D and greater blood cis-1,3-D AUCs were attained with microencapsulated 1,3-D than with neat cis-' 3 C-1,3-D ( Fig. 1 and 3 ). Increased cis-1,3-D blood levels resulted in a net effect of higher total {cis-plus trans-isomers) 1,3-D than total 13 C-1,3-D blood levels as demonstrated in 9/10 trials conducted in Phase II and Kastl, 1986). Roughly 3-fold more cis-than trans-1,3-D has been reported to undergo glutathione conjugation (Dietz et ai, 1984b; Waechter and Kastl, 1988) and, as noted, the gastric mucosa contains a relatively high concentration of glutathione. Absorbed trans-l,3-D primarily undergoes an equally rapid hydroxylation and loss of its 3-position chlorine (Diet et at, 1984b; Waechter and Kastl, 1988) , presumably distal from the site of its absorption. Subsequently, elimination of 1,3-D was biphasic in nature with half-lives during the relatively prominent initial, alpha, phase of excretion ranged from 4.7 to 6.9 min and the slower, beta, phase of elimination exhibiting a half-life of roughly 20-43 min. Blood concentrations typically decreased > 10-fold within 20 min postdosing.
Blood kinetic data for orally administered 1,3-D are consistent with the findings of Stott and Kastl (1986) in which a biphasic elimination of 1,3-D with a prominent alpha phase (2-6 min half-life) followed by a slower beta phase (33-43 min half-life) was observed in rats inhaling cis-and trans-1,3-D vapor. As in the present study, trans-1,3-D blood levels were consistently found to be higher than cis-1,3-D in exposed rats, presumably via protein binding and glutathione conjugation within the respiratory tract. The peak blood levels of up to 127 ppb cis-1,3-D and 286 ppb trans-1,3-D in rats administered 25 mg/kg microencapsulated 1,3-D via gavage in the present study roughly compare with steady-state blood levels of 200 ppb cis-1,3-D and 260 ppb trans-1,3-D reported in rats inhaling 90 ppm racemic 1,3-D vapor for > 1 hr in the earlier inhalation study. The disproportionately lower peak blood levels of cis-1,3-D in the former rats may reflect a more active conjugation of this isomer with glutathione in the gastric mucosa relative to the pulmonary tract.
In conclusion, the results of this study confirm the ready bioavailability of microencapsulated 1,3-D once ingested by rats. Absorption of microencapsulated 1,3-D occurs rapidly and may even result in higher blood levels, and thus higher systemic exposure, than an identical dosage of neat 1,3-D. Following absorption, the relatively rapid elimination from the blood stream was essentially the same for 1,3-D originating from either form of the orally dosed material or from inhaled 1,3-D.
